Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM
Status:
Not yet recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
In this multicenter, randomized, open-label, parallel-controlled, non-inferiority clinical
trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily will
be compared with degludec/insulin aspart (IDegAsp) once daily plus insulin aspart (IAsp)
twice daily after 16weeks of treatment in patients with type 2 diabetes mellitus. This trial
will enable primary assessment of the clinically relevant endpoint of a change in HbA1c.